A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 3, Issue 4, 2017, Pages 622-635

  Villemagne, Victor L ^a,b   Rowe, Christopher C ^a,b   Barnham, Kevin J ^b   Cherny, Robert ^b,c   Woodward, Michael ^a   Bozinosvski, Svetlana ^a   Salvado, Olivier ^d   Bourgeat, Pierrick ^d   Perez, Keyla ^b   Fowler, Christopher ^b   Rembach, Alan ^b   Maruff, Paul ^b,e   Ritchie, Craig ^f   Tanzi, Rudy ^g   Masters, Colin L ^b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Prana Biotechnology   (Australia)

^d CSIRO   (Australia)

^e Scientific Division   (Australia)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; A amyloid PET molecular imaging; Biomarkers for Alzheimer's disease; Clinical trial design; Novel 8 OH quinoline; Randomised control trial

Indexed keywords

8 HYDROXY QUINOLIN [2 (DIMETHYLAMINO)METHYL 5,7 DICHLORO 8 HYDROXYQUINONE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; PLACEBO; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN METABOLISM; BRAIN SIZE; CARDIOVASCULAR DISEASE; CEREBELLUM CORTEX; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXECUTIVE FUNCTION; EYE DISEASE; FRONTAL CORTEX; GASTROINTESTINAL SYMPTOM; GENOTYPE; GLUCOSE METABOLISM; GRAY MATTER; HAPLOTYPE; HUMAN; IMAGE RECONSTRUCTION; IMMUNOPATHOLOGY; INFECTION; INJURY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; MOLECULAR IMAGING; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; TEMPORAL CORTEX;

EID: 85034792669     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2017.10.001     Document Type: Article

References (41)

1. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7 (2011), 280–292.
2. Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
3. Blennow, K., Mattsson, N., Scholl, M., Hansson, O., Zetterberg, H., Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 36 (2015), 297–309.
4. Clark, C.M., Pontecorvo, M.J., Beach, T.G., Bedell, B.J., Coleman, R.E., Doraiswamy, P.M., et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11 (2012), 669–678.
5. Matveev, S.V., Spielmann, H.P., Metts, B.M., Chen, J., Onono, F., Zhu, H., et al. A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. J Neurochem 131 (2014), 356–368.
6. Patterson, B.W., Elbert, D.L., Mawuenyega, K.G., Kasten, T., Ovod, V., Ma, S., et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 78 (2015), 439–453.
7. Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D.J., et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 71 (2014), 1282–1289.
8. Li, Q.X., Villemagne, V.L., Doecke, J.D., Rembach, A., Sarros, S., Varghese, S., et al. Alzheimer's disease normative cerebrospinal fluid biomarkers validated in PET amyloid-β characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimers Dis 48 (2015), 175–187.
9. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12 (2013), 357–367.
10. Jack, C.R., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., et al. Brain β-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
11. Toledo, J.B., Xie, S.X., Trojanowski, J.Q., Shaw, L.M., Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol 126 (2013), 659–670.
12. Adlard, P.A., Cherny, R.A., Finkelstein, D.I., Gautier, E., Robb, E., Cortes, M., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59 (2008), 43–55.
13. Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001), 665–676.
14. Ryan, T.M., Roberts, B.R., McColl, G., Hare, D.J., Doble, P.A., Li, Q.X., et al. Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease. J Neurosci 35 (2015), 2871–2884.
15. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7 (2008), 779–786.
16. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
17. Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., DeKosky, S.T., Barberger-Gateau, P., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9 (2010), 1118–1127.
18. Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69 (2011), 181–192.
19. Good, C.D., Johnsrude, I.S., Ashburner, J., Henson, R.N., Friston, K.J., Frackowiak, R.S., A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14 (2001), 21–36.
20. Ellis, K.A., Szoeke, C., Bush, A.I., Darby, D., Graham, P.L., Lautenschlager, N.T., et al. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr 26 (2014), 543–554.
21. Rembach, A., Faux, N.G., Watt, A.D., Pertile, K.K., Rumble, R.L., Trounson, B.O., et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 10 (2014), 53–61.
22. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
23. Liu-Seifert, H., Siemers, E., Holdridge, K.C., Andersen, S.W., Lipkovich, I., Carlson, C., et al. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimers Dement 1 (2015), 111–121.
24. Siemers, E.R., Sundell, K.L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12 (2015), 110–120.
25. Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P.H., Williams, L., Maier, M., et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537 (2016), 50–56 [Addendum. Nature. 2017;2546:2564].
26. De Strooper, B., Lessons from a failed γ-secretase Alzheimer trial. Cell 159 (2014), 721–726.
27. Strömberg, K., Eketjäll, S., Georgievska, B., Tunblad, K., Eliason, K., Olsson, F., et al. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production. FEBS J 282 (2015), 65–73.
28. Karran, E., Hardy, J., A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 76 (2014), 185–205.
29. Jawhar, S., Wirths, O., Schilling, S., Graubner, S., Demuth, H.U., Bayer, T.A., Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem 286 (2011), 4454–4460.
30. Izzo, N.J., Xu, J., Zeng, C., Kirk, M.J., Mozzoni, K., Silky, C., et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE, 9, 2014, e111899.
31. LeVine, H. 3rd, Ding, Q., Walker, J.A., Voss, R.S., Augelli-Szafran, C.E., Clioquinol and other hydroxyquinoline derivatives inhibit Aβ(1-42) oligomer assembly. Neurosci Lett 465 (2009), 99–103.
32. Matlack, K.E., Tardiff, D.F., Narayan, P., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., et al. Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci U S A 111 (2014), 4013–4018.
33. Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 14 (2015), 39–47.
34. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31 (2010), 1275–1283.
35. Strobel, G., Solanezumab: Did Aβ 'reflux' from blood confound target engagement in CSF? [Internet]. 2017 Available at: http://www.alzforum.org/print-series/745106. Accessed October 11, 2017.
36. Liu, E., Schmidt, M.E., Margolin, R., Sperling, R., Koeppe, R., Mason, N.S., et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85 (2015), 692–700.
37. Villemagne, V.L., Doré, V., Yates, P., Brown, B., Mulligan, R., Bourgeat, P., et al. En attendant centiloid. 2014. Adv Res 2 (2014), 723–729.
38. Clinical Trials.gov [Internet]. Registration number: NCT02245737. An efficacy and safety study of LY3314814 in early Alzheimer's disease (AMARANTH); 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02245737?term=AZD3293&rank=8. Accessed October 11, 2017.
39. Weigand, S.D., Vemuri, P., Wiste, H.J., Senjem, M.L., Pankratz, V.S., Aisen, P.S., et al. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement 7 (2011), 133–141.
40. Schneider, L.S., Lahiri, D.K., The perils of Alzheimer's drug development. Curr Alzheimer Res 6 (2009), 77–78.
41. Strobel, G., As DIAN plans trial number two, the goal is to go big. ALZFORUM [Internet]. 2015 Available at: http://www.alzforum.org/news/conference-coverage/dian-plans-trial-number-two-goal-go-big. Accessed October 11, 2017.